Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Sees Significant Growth in Short Interest

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 10,430,000 shares, a growth of 28.9% from the March 31st total of 8,090,000 shares. Currently, 2.2% of the company’s stock are sold short. Based on an average trading volume of 4,090,000 shares, the days-to-cover ratio is currently 2.6 days.

Analyst Ratings Changes

Several equities analysts have commented on CATX shares. B. Riley increased their price target on shares of Perspective Therapeutics from $1.20 to $1.70 and gave the company a “buy” rating in a research note on Tuesday, April 9th. Oppenheimer reaffirmed an “outperform” rating and issued a $1.50 target price (up from $1.20) on shares of Perspective Therapeutics in a research report on Monday, April 1st.

Insider Transactions at Perspective Therapeutics

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were bought at an average price of 0.95 per share, for a total transaction of 57,409,487.05. Following the acquisition, the insider now directly owns 116,773,394 shares in the company, valued at 110,934,724.30. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 5.72% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. ZWJ Investment Counsel Inc. purchased a new position in Perspective Therapeutics in the first quarter valued at about $26,000. Simplicity Wealth LLC acquired a new position in Perspective Therapeutics during the first quarter worth $40,000. Bank of New York Mellon Corp purchased a new stake in Perspective Therapeutics during the third quarter worth $42,000. Taylor & Morgan Wealth Management LLC grew its holdings in Perspective Therapeutics by 8.7% in the fourth quarter. Taylor & Morgan Wealth Management LLC now owns 625,000 shares of the company’s stock valued at $251,000 after purchasing an additional 50,000 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new stake in Perspective Therapeutics in the third quarter valued at $314,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Stock Down 1.3 %

Shares of NYSEAMERICAN:CATX opened at 1.58 on Friday. Perspective Therapeutics has a fifty-two week low of 0.21 and a fifty-two week high of 1.77. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $927.33 million, a PE ratio of -15.80 and a beta of 1.56.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.